King's College London

Research portal

Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study

Research output: Contribution to journalArticlepeer-review

Sailish Honap, Lulia Al-Hillawi, Samantha Baillie, Aaron Bancil, Lawrence Matini, Rebecca Lau, Klaartje Bel Kok, Kamal Patel, Alissa Walsh, Peter M Irving, Mark A Samaan

Original languageEnglish
Article numberflgastro-2022-102168
Pages (from-to)517-523
Number of pages7
JournalFrontline Gastroenterology
Volume13
Issue number6
DOIs
Accepted/In press18 Apr 2022
Published28 Apr 2022

Bibliographical note

Publisher Copyright: ©

Documents

King's Authors

Abstract

Objective: Ustekinumab is an interleukin-12/interleukin-23 receptor antagonist licensed for the treatment of ulcerative colitis (UC). Clinical trial data were promising; however, real-world data are limited. We assessed the safety and effectiveness of ustekinumab in UC in a real-world setting. Design/method: This was a multicentre, retrospective, observational cohort study between February 2020 and January 2022. Disease activity was assessed using the Simple Clinical Colitis Activity Index (SCCAI). Clinical remission was defined as a SCCAI≤2. The primary endpoints were rates of corticosteroid-free remission (CSFR) at week 16 and at week 26. Objective outcomes, including faecal calprotectin (FCAL), were also collected. Results: 110 patients with UC (65% male; median age 40 (IQR range 29-59); 96% with prior biologic and/or tofacitinib exposure) had a median follow-up of 28 weeks (IQR 17-47). CSFR was 36% (18/50) at week 16% and 33% (13/39) at week 26, corresponding with a significant fall in SCCAI from 6 (IQR 4-8) at baseline to 3 (IQR 0-5) at week 26, p<0.001. By week 16, there was improvement of median FCAL measurements, which fell from a baseline of 610 μg/g (IQR 333-1100) to 102 μg/g (IQR 54-674) at week 16. At the end of follow-up, 15% (17/110) had discontinued treatment; 13 patients due to primary non-response or loss of response, and 1 patient for family planning. Treatment was discontinued in three patients due to adverse events. Conclusion: In the largest real-world study to date, ustekinumab was effective with a reassuring safety profile in a refractory cohort of patients.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454